Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALVAL.PA
- Price
- 1.05
- Stock movement up
- +0.03 (3.10%)
- Company name
- Valbiotis SAS
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 16.55M
- Ent value
- -
- Price/Sales
- 3.47
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -14.65%
- 1 year return
- -72.90%
- 3 year return
- -46.09%
- 5 year return
- -20.76%
- 10 year return
- -
Last updated: 2025-04-09
DIVIDENDS
ALVAL.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.47 |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 15.76M |
| EPS (TTM) | -0.87 |
| FCF per share (TTM) | -0.91 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.77M |
| Gross profit (TTM) | 1.75M |
| Operating income (TTM) | -10.87M |
| Net income (TTM) | -10.87M |
| EPS (TTM) | -0.87 |
| EPS (1y forward) | -0.44 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 36.63% |
| Operating margin (TTM) | -228.12% |
| Profit margin (TTM) | -228.07% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 0.00 |
| Net receivables | 0.00 |
| Total current assets | 0.00 |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 0.00 |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 0.00 |
| Total liabilities | 0.00 |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.25M |
| Capital expenditures (TTM) | 27.00K |
| Free cash flow (TTM) | -11.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.12 |
| Daily high | 1.17 |
| Daily low | 1.02 |
| Daily Volume | 71K |
| All-time high | 10.54 |
| 1y analyst estimate | 6.35 |
| Beta | -0.16 |
| EPS (TTM) | -0.87 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 25 Apr 2025 |
Downside potential
Loading...
Downside potential data
| ALVAL.PA | S&P500 | |
| Current price drop from All-time high | -90.03% | -19.00% |
| Highest price drop | -90.33% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -52.89% | -11.07% |
| Avg time to new high | 401 days | 12 days |
| Max time to new high | 2001 days | 1805 days |
COMPANY DETAILS
Marketcap
16.55M
Marketcap category
Small-cap
Description
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Employees
52
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found